epidemiological and medical burden of the covid-19
TRANSCRIPT
![Page 1: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/1.jpg)
1
EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19 PANDEMIC IN PEDIATRIC TRANSPLANT RECIPIENTS: A CROSS-SECTIONAL STUDY ACROSS THE ERN-TRANSPLANTCHILD MEMBERS
Fields marked with * are mandatory.
EPIDEMIOLOGICAL AND MEDICAL BURDEN OF
THE COVID-19 PANDEMIC IN PEDIATRIC TRANSPLANT RECIPIENTS: A CROSS-SECTIONAL STUDY ACROSS THE ERN-
TRANSPLANTCHILD MEMBERS
![Page 2: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/2.jpg)
2
D e a r c o l l e a g u e s ,
After the successful first clinical audit about COVID-19 in pediatric transplanted patients across ERN-TransplantChild members, Padova team suggested to share the data about follow up and burden of the COVID-19 pandemic in pediatric transplant recipients among TransplantChild centres. We see this survey as the continuation of the first one and an opportunity to update the experience and knowledge on the effects of the SARS-CoV-2 i n f e c t i o n i n o u r p a t i e n t s .
Please with the results of the first clinical audit.find below the file
This audit, on "Epidemiological and medical burden of the COVID-19 pandemic in is a survey about your centre approach and resources pediatric transplant recipients"
related to SARS-CoV-2 infection and clinical case description and follow up of these patients.
A first draft of the survey was elaborated by Dr. M. Cananzi, Dr. E. Benetti, Dr. F. de Corti, Dr. D. Donà and Dr. G. Perilongo from Azienda Ospedalera di Padova and after suggestions of other members, modifications were incorporated resulting in the final survey format that we are now sending to all of you.
It would be great to have your responses throughout this month of , so that we can Aprilanalyze the results and prepare the first document with them in May.
As always, here at La Paz University Hospital we will be completely willing to collaborate in everything you need.
Thanks in advance for your collaboration, and we are looking forward to hearing from you.
Find below the article we published on the previous COVID-19 survey.2020_Pediatric_transplantation_in_Europe_during_the_COVID-
19_pandemic_Early_impact_on_activity_and_healthcare.pdf
Your name
CentreVilnius University Hospital Santaros Klinikos, LithuaniaCentro Hospitalar e Universitário de Coimbra, Portugal
*
*
*
![Page 3: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/3.jpg)
3
University Medical Center Utrecht, The NetherlandsChildren's Memorial Health Institute, PolandHospital Universitario la Paz, EspañaMedizinische Hochschule Hannover, GermanyCentro Hospitalar de Lisboa Norte, PortugalOspedale Papa Giovanni XXIII, Bergamo, ItalyCentro Hospitalar do Porto, PortugalKarolinska University Hospital, SwedenAssistance Publique Hôpitaux de Paris, Hôpital Bicêtre, FranceAssistance Publique Hôpitaux de Paris, Hôpital Necker Enfants Malades, FranceSkåne University Hospital, Lund, SwedenOspedale Pediatrico Bambino Gesù, Rome, ItalyUniversity Hospitals Saint Luc, BelgiumAzienda Ospedale Università Padova, ItalyISMETT Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, ItalyCentre for Pediatric Lung Transplantation, Medical University of Vienna, AustriaUniversity Hospital Centre Zagreb, CroatiaSemmelweis University, HungaryTartu University Hospital, EstoniaChildren’s Clinical University Hospital, Riga, LatviaCentre Hospitalier du Luxembourg, LuxembourgMater Dei Hospital, MaltaRigshospitalet University Hospital, DenmarkOdense University Hospital, DenmarkOther
Please, specify other centre name:
CENTRE-SPECIFIC QUESTIONS
Transplantation program:HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
Characteristics of your Transplant Unit:MedicalSurgicalBoth
*
*
*
![Page 4: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/4.jpg)
4
%
patients
Type of patients:Exclusively pediatricMixed pediatric-adult
How many children with SOT/HSCT do you follow?<5051-100101-149150-199>200
WHO COVID-19 def ini t ion of conf i rmed case*
*Please answer according to the WHO COVID-19 definition of the confirmed case as either:A. a child with a positive Nucleic Acid Amplification Test (NAAT); B. a child with a positive SARS-CoV-2 antigen-rapid diagnostic test (RDT) who meets clinical criteria and is a contact of a probable or confirmed case or is linked to a COVID-19 cluster;or C. an asymptomatic child with a positive SARS-CoV-2 antigen-RDT who is a contact of a probable or c o n f i r m e d c a s e .
*See attached WHO confirmed case definition for more details, if needed. WHO-2019-nCoV-Surveillance_Case_Definition-2020.2-eng.pdf
How many of your transplanted patients have been infected by since the beginning of the SARS-CoV-2*pandemic?
Only values between 0 and 100 are allowed
Percentage of your total patients:Only values between 0 and 100 are allowed
In your centre, have you specific test to assess the specific immune response to SARS-CoV-2?IgG anti-SARS-CoV-2 titrationB lymphocyte specific responseT lymphocyte specific responseCytokines productionOtherNone
Please, specify B lymphocyte specific response technique or method:
*
*
*
*
*
*
![Page 5: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/5.jpg)
5
months
Please, specify T lymphocyte specific response technique or method:
Please, specify cytokines production technique or method:
Please, specify other technique or methods used:
Please, fill in the specific questions for each patient with COVID-19 you have. Once you have finished, go to the Submit section to finish the survey.
1. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy
*
*
*
![Page 6: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/6.jpg)
6
- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic
![Page 7: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/7.jpg)
7
- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq
![Page 8: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/8.jpg)
8
- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia
![Page 9: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/9.jpg)
9
- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo
![Page 10: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/10.jpg)
10
- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidneyLiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
![Page 11: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/11.jpg)
11
months* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acid
![Page 12: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/12.jpg)
12
Everolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:
![Page 13: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/13.jpg)
13
NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia sppStaphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenza
![Page 14: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/14.jpg)
14
JC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:Normal
![Page 15: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/15.jpg)
15
Reduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
![Page 16: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/16.jpg)
16
weeks
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
![Page 17: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/17.jpg)
17
weeks
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:*
![Page 18: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/18.jpg)
18
days
days
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
![Page 19: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/19.jpg)
19
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
![Page 20: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/20.jpg)
20
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
2. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
![Page 21: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/21.jpg)
21
Country of residence (EU member states):AT - AustriaBE - BelgiumBG - BulgariaHR - CroatiaCY - CyprusCZ - CzechiaDK - DenmarkEE - EstoniaFI - FinlandFR - FranceDE - GermanyEL - GreeceHU - HungaryIE - IrelandIT - ItalyLV - LatviaLT - LithuaniaLU - LuxembourgMT - MaltaNL - NetherlandsPL - PolandPT - PortugalRO - RomaniaSK - Slovak RepublicSI - SloveniaES - SpainSE - Sweden
Country of residence (Non- EU member sate):AF - AfghanistanAL - AlbaniaDZ - AlgeriaAD - AndorraAO - AngolaAG - Antigua and BarbudaAR - ArgentinaAM - ArmeniaAU - AustraliaAT - AustriaAZ - AzerbaijanBS - BahamasBH - BahrainBD - BangladeshBB - BarbadosBY - Belarus
![Page 22: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/22.jpg)
22
BE - BelgiumBZ - BelizeBJ - BeninBT - BhutanBO - BoliviaBA - Bosnia and HerzegovinaBW - BotswanaBR - BrazilBN - Brunei DarussalamBG - BulgariaBF - Burkina FasoBI - BurundiCV - Cabo VerdeKH - CambodiaCM - CameroonCA - CanadaCF - Central African RepublicTD - ChadCL - ChileCN - ChinaCO - ColombiaKM - ComorosCG - CongoCR - Costa RicaCI - Côte D'IvoireHR - CroatiaCU - CubaCY - CyprusCZ - CzechiaCD - Democratic Republic of the CongoDK - DenmarkDJ - DjiboutiDM - DominicaDO - Dominican RepublicEC - EcuadorEG - EgyptSV - El SalvadorGQ - Equatorial GuineaER - EritreaEE - EstoniaSZ - EswatiniET - EthiopiaFJ - FijiFI - FinlandFR - FranceGA - GabonGM - Gambia
![Page 23: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/23.jpg)
23
GE - GeorgiaDE - GermanyGH - GhanaGR - GreeceGD - GrenadaGT - GuatemalaGN - GuineaGW - Guinea BissauGY - GuyanaHT - HaitiHN - HondurasHU - HungaryIS - IcelandIN - IndiaID - IndonesiaIR - IranIQ - IraqIE - IrelandIL - IsraelIT - ItalyJM - JamaicaJP - JapanJO - JordanKZ - KazakhstanKE - KenyaKI - KiribatiKW - KuwaitKG - KyrgyzstanLA - LaosLV - LatviaLB - LebanonLS - LesothoLR - LiberiaLY - LibyaLI - LiechtensteinLT - LithuaniaLU - LuxembourgMG - MadagascarMW - MalawiMY - MalaysiaMV - MaldivesML - MaliMT - MaltaMH - Marshall IslandsMR - MauritaniaMU - MauritiusMX - Mexico
![Page 24: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/24.jpg)
24
FM - MicronesiaMC - MonacoMN - MongoliaME - MontenegroMA - MoroccoMZ - MozambiqueMM - MyanmarNA - NamibiaNR - NauruNP - NepalNL - NetherlandsNZ - New ZealandNI - NicaraguaNE - NigerNG - NigeriaKP - North KoreaMK - North MacedoniaNO - NorwayOM - OmanPK - PakistanPW - PalauPA - PanamaPG - Papua New GuineaPY - ParaguayPE - PeruPH - PhilippinesPL - PolandPT - PortugalQA - QatarMD - Republic of MoldovaRO - RomaniaRU - Russian FederationRW - RwandaKN - Saint Kitts and NevisLC - Saint LuciaVC - Saint Vincent and the GrenadinesWS - SamoaSM - San MarinoST - Sao Tome and PrincipeSA - Saudi ArabiaSN - SenegalRS - SerbiaSC - SeychellesSL - Sierra LeoneSG - SingaporeSK - SlovakiaSI - Slovenia
![Page 25: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/25.jpg)
25
SB - Solomon IslandsSO - SomaliaZA - South AfricaKR - South KoreaSS - South SudanES - SpainLK - Sri LankaSD - SudanSR - SurinameSE - SwedenCH - SwitzerlandSY - Syrian Arab RepublicTJ - TajikistanTZ - TanzaniaTH - ThailandTL - Timor-LesteTG - TogoTO - TongaTT - Trinidad and TobagoTN - TunisiaTR - TurkeyTM - TurkmenistanTV - TuvaluUG - UgandaUA - UkraineAE - United Arab EmiratesGB - United KingdomUS - United States of AmericaUY - UruguayUZ - UzbekistanVU - VanuatuVE - VenezuelaVN - Viet NamYE - YemenZM - ZambiaZW - Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
![Page 26: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/26.jpg)
26
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
![Page 27: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/27.jpg)
27
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
![Page 28: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/28.jpg)
28
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
![Page 29: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/29.jpg)
29
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
![Page 30: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/30.jpg)
30
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
![Page 31: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/31.jpg)
31
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
![Page 32: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/32.jpg)
32
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
![Page 33: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/33.jpg)
33
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
![Page 34: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/34.jpg)
34
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
![Page 35: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/35.jpg)
35
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
![Page 36: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/36.jpg)
36
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
3. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
![Page 37: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/37.jpg)
37
Country of residence (EU member states):[ID85] - Austria[ID86] - Belgium[ID87] - Bulgaria[ID88] - Croatia[ID89] - Cyprus[ID90] - Czechia[ID91] - Denmark[ID92] - Estonia[ID93] - Finland[ID94] - France[ID95] - Germany[ID96] - Greece[ID97] - Hungary[ID98] - Ireland[ID99] - Italy[ID100] - Latvia[ID101] - Lithuania[ID102] - Luxembourg[ID103] - Malta[ID104] - Netherlands[ID105] - Poland[ID106] - Portugal[ID107] - Romania[ID108] - Slovak Republic[ID109] - Slovenia[ID110] - Spain[ID111] - Sweden
Country of residence (Non- EU member sate):[ID113] - Afghanistan[ID114] - Albania[ID115] - Algeria[ID116] - Andorra[ID117] - Angola[ID118] - Antigua and Barbuda[ID119] - Argentina[ID120] - Armenia[ID121] - Australia[ID122] - Austria[ID123] - Azerbaijan[ID668] - Bahamas[ID669] - Bahrain[ID670] - Bangladesh[ID671] - Barbados[ID672] - Belarus
![Page 38: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/38.jpg)
38
[ID673] - Belgium[ID689] - Belize[ID690] - Benin[ID691] - Bhutan[ID692] - Bolivia[ID693] - Bosnia and Herzegovina[ID694] - Botswana[ID695] - Brazil[ID696] - Brunei Darussalam[ID697] - Bulgaria[ID698] - Burkina Faso[ID699] - Burundi[ID700] - Cabo Verde[ID701] - Cambodia[ID702] - Cameroon[ID703] - Canada[ID704] - Central African Republic[ID705] - Chad[ID706] - Chile[ID707] - China[ID708] - Colombia[ID709] - Comoros[ID710] - Congo[ID711] - Costa Rica[ID716] - Côte D'Ivoire[ID712] - Croatia[ID713] - Cuba[ID714] - Cyprus[ID715] - Czechia[ID717] - Democratic Republic of the Congo[ID718] - Denmark[ID719] - Djibouti[ID720] - Dominica[ID721] - Dominican Republic[ID722] - Ecuador[ID723] - Egypt[ID724] - El Salvador[ID725] - Equatorial Guinea[ID726] - Eritrea[ID727] - Estonia[ID728] - Eswatini[ID729] - Ethiopia[ID730] - Fiji[ID731] - Finland[ID732] - France[ID733] - Gabon[ID734] - Gambia
![Page 39: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/39.jpg)
39
[ID735] - Georgia[ID736] - Germany[ID737] - Ghana[ID738] - Greece[ID739] - Grenada[ID740] - Guatemala[ID741] - Guinea[ID742] - Guinea Bissau[ID743] - Guyana[ID744] - Haiti[ID745] - Honduras[ID746] - Hungary[ID747] - Iceland[ID748] - India[ID749] - Indonesia[ID750] - Iran[ID751] - Iraq[ID752] - Ireland[ID753] - Israel[ID754] - Italy[ID755] - Jamaica[ID756] - Japan[ID757] - Jordan[ID758] - Kazakhstan[ID759] - Kenya[ID760] - Kiribati[ID761] - Kuwait[ID762] - Kyrgyzstan[ID763] - Laos[ID764] - Latvia[ID765] - Lebanon[ID766] - Lesotho[ID767] - Liberia[ID768] - Libya[ID769] - Liechtenstein[ID770] - Lithuania[ID771] - Luxembourg[ID772] - Madagascar[ID773] - Malawi[ID774] - Malaysia[ID775] - Maldives[ID776] - Mali[ID777] - Malta[ID778] - Marshall Islands[ID779] - Mauritania[ID780] - Mauritius[ID781] - Mexico
![Page 40: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/40.jpg)
40
[ID782] - Micronesia[ID783] - Monaco[ID784] - Mongolia[ID785] - Montenegro[ID786] - Morocco[ID787] - Mozambique[ID788] - Myanmar[ID789] - Namibia[ID790] - Nauru[ID791] - Nepal[ID792] - Netherlands[ID793] - New Zealand[ID794] - Nicaragua[ID795] - Niger[ID796] - Nigeria[ID797] - North Korea[ID798] - North Macedonia[ID799] - Norway[ID800] - Oman[ID801] - Pakistan[ID802] - Palau[ID803] - Panama[ID804] - Papua New Guinea[ID805] - Paraguay[ID806] - Peru[ID807] - Philippines[ID808] - Poland[ID809] - Portugal[ID810] - Qatar[ID811] - Republic of Moldova[ID812] - Romania[ID813] - Russian Federation[ID814] - Rwanda[ID815] - Saint Kitts and Nevis[ID816] - Saint Lucia[ID817] - Saint Vincent and the Grenadines[ID818] - Samoa[ID819] - San Marino[ID820] - Sao Tome and Principe[ID821] - Saudi Arabia[ID822] - Senegal[ID823] - Serbia[ID824] - Seychelles[ID825] - Sierra Leone[ID826] - Singapore[ID827] - Slovakia[ID828] - Slovenia
![Page 41: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/41.jpg)
41
[ID829] - Solomon Islands[ID830] - Somalia[ID831] - South Africa[ID832] - South Korea[ID833] - South Sudan[ID834] - Spain[ID835] - Sri Lanka[ID836] - Sudan[ID837] - Suriname[ID838] - Sweden[ID839] - Switzerland[ID840] - Syrian Arab Republic[ID841] - Tajikistan[ID842] - Tanzania[ID843] - Thailand[ID844] - Timor-Leste[ID845] - Togo[ID846] - Tonga[ID847] - Trinidad and Tobago[ID848] - Tunisia[ID849] - Turkey[ID850] - Turkmenistan[ID851] - Tuvalu[ID852] - Uganda[ID853] - Ukraine[ID854] - United Arab Emirates[ID855] - United Kingdom[ID856] - United States of America[ID857] - Uruguay[ID858] - Uzbekistan[ID859] - Vanuatu[ID860] - Venezuela[ID861] - Viet Nam[ID862] - Yemen[ID863] - Zambia[ID864] - Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
![Page 42: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/42.jpg)
42
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
![Page 43: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/43.jpg)
43
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
![Page 44: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/44.jpg)
44
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
![Page 45: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/45.jpg)
45
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
![Page 46: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/46.jpg)
46
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
![Page 47: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/47.jpg)
47
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
![Page 48: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/48.jpg)
48
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
![Page 49: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/49.jpg)
49
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
![Page 50: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/50.jpg)
50
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
![Page 51: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/51.jpg)
51
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
![Page 52: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/52.jpg)
52
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
4. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
![Page 53: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/53.jpg)
53
Country of residence (EU member states):[ID1122] - Austria[ID1123] - Belgium[ID1139] - Bulgaria[ID1140] - Croatia[ID1141] - Cyprus[ID1142] - Czechia[ID1143] - Denmark[ID1144] - Estonia[ID1145] - Finland[ID1146] - France[ID1147] - Germany[ID1148] - Greece[ID1149] - Hungary[ID1150] - Ireland[ID1151] - Italy[ID1152] - Latvia[ID1153] - Lithuania[ID1154] - Luxembourg[ID1155] - Malta[ID1156] - Netherlands[ID1157] - Poland[ID1158] - Portugal[ID1159] - Romania[ID1160] - Slovak Republic[ID1161] - Slovenia[ID1162] - Spain[ID1163] - Sweden
Country of residence (Non- EU member sate):[ID1165] - Afghanistan[ID1166] - Albania[ID1167] - Algeria[ID1168] - Andorra[ID1169] - Angola[ID1170] - Antigua and Barbuda[ID1171] - Argentina[ID1172] - Armenia[ID1173] - Australia[ID1174] - Austria[ID1175] - Azerbaijan[ID1176] - Bahamas[ID1177] - Bahrain[ID1178] - Bangladesh[ID1179] - Barbados[ID1180] - Belarus
![Page 54: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/54.jpg)
54
[ID1181] - Belgium[ID1182] - Belize[ID1183] - Benin[ID1184] - Bhutan[ID1185] - Bolivia[ID1186] - Bosnia and Herzegovina[ID1187] - Botswana[ID1188] - Brazil[ID1189] - Brunei Darussalam[ID1190] - Bulgaria[ID1191] - Burkina Faso[ID1192] - Burundi[ID1193] - Cabo Verde[ID1194] - Cambodia[ID1195] - Cameroon[ID1196] - Canada[ID1197] - Central African Republic[ID1198] - Chad[ID1199] - Chile[ID1200] - China[ID1201] - Colombia[ID1202] - Comoros[ID1203] - Congo[ID1204] - Costa Rica[ID1209] - Côte D'Ivoire[ID1205] - Croatia[ID1206] - Cuba[ID1207] - Cyprus[ID1208] - Czechia[ID1210] - Democratic Republic of the Congo[ID1211] - Denmark[ID1212] - Djibouti[ID1213] - Dominica[ID1214] - Dominican Republic[ID1215] - Ecuador[ID1216] - Egypt[ID1217] - El Salvador[ID1218] - Equatorial Guinea[ID1219] - Eritrea[ID1220] - Estonia[ID1221] - Eswatini[ID1222] - Ethiopia[ID1223] - Fiji[ID1224] - Finland[ID1225] - France[ID1226] - Gabon[ID1227] - Gambia
![Page 55: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/55.jpg)
55
[ID1228] - Georgia[ID1229] - Germany[ID1230] - Ghana[ID1231] - Greece[ID1232] - Grenada[ID1233] - Guatemala[ID1234] - Guinea[ID1235] - Guinea Bissau[ID1236] - Guyana[ID1237] - Haiti[ID1238] - Honduras[ID1239] - Hungary[ID1240] - Iceland[ID1241] - India[ID1242] - Indonesia[ID1243] - Iran[ID1244] - Iraq[ID1245] - Ireland[ID1246] - Israel[ID1247] - Italy[ID1248] - Jamaica[ID1249] - Japan[ID1250] - Jordan[ID1251] - Kazakhstan[ID1252] - Kenya[ID1253] - Kiribati[ID1254] - Kuwait[ID1255] - Kyrgyzstan[ID1256] - Laos[ID1257] - Latvia[ID1258] - Lebanon[ID1259] - Lesotho[ID1260] - Liberia[ID1261] - Libya[ID1262] - Liechtenstein[ID1263] - Lithuania[ID1264] - Luxembourg[ID1265] - Madagascar[ID1266] - Malawi[ID1267] - Malaysia[ID1268] - Maldives[ID1269] - Mali[ID1270] - Malta[ID1271] - Marshall Islands[ID1272] - Mauritania[ID1273] - Mauritius[ID1274] - Mexico
![Page 56: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/56.jpg)
56
[ID1275] - Micronesia[ID1276] - Monaco[ID1277] - Mongolia[ID1278] - Montenegro[ID1279] - Morocco[ID1280] - Mozambique[ID1281] - Myanmar[ID1282] - Namibia[ID1283] - Nauru[ID1284] - Nepal[ID1285] - Netherlands[ID1286] - New Zealand[ID1287] - Nicaragua[ID1288] - Niger[ID1289] - Nigeria[ID1290] - North Korea[ID1291] - North Macedonia[ID1292] - Norway[ID1293] - Oman[ID1294] - Pakistan[ID1295] - Palau[ID1296] - Panama[ID1297] - Papua New Guinea[ID1298] - Paraguay[ID1299] - Peru[ID1300] - Philippines[ID1301] - Poland[ID1302] - Portugal[ID1303] - Qatar[ID1304] - Republic of Moldova[ID1305] - Romania[ID1306] - Russian Federation[ID1307] - Rwanda[ID1308] - Saint Kitts and Nevis[ID1309] - Saint Lucia[ID1310] - Saint Vincent and the Grenadines[ID1311] - Samoa[ID1312] - San Marino[ID1313] - Sao Tome and Principe[ID1314] - Saudi Arabia[ID1315] - Senegal[ID1316] - Serbia[ID1317] - Seychelles[ID1318] - Sierra Leone[ID1319] - Singapore[ID1320] - Slovakia[ID1321] - Slovenia
![Page 57: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/57.jpg)
57
[ID1322] - Solomon Islands[ID1323] - Somalia[ID1324] - South Africa[ID1325] - South Korea[ID1326] - South Sudan[ID1327] - Spain[ID1328] - Sri Lanka[ID1329] - Sudan[ID1330] - Suriname[ID1331] - Sweden[ID1332] - Switzerland[ID1333] - Syrian Arab Republic[ID1334] - Tajikistan[ID1335] - Tanzania[ID1336] - Thailand[ID1337] - Timor-Leste[ID1338] - Togo[ID1339] - Tonga[ID1340] - Trinidad and Tobago[ID1341] - Tunisia[ID1342] - Turkey[ID1343] - Turkmenistan[ID1344] - Tuvalu[ID1345] - Uganda[ID1346] - Ukraine[ID1347] - United Arab Emirates[ID1348] - United Kingdom[ID1349] - United States of America[ID1350] - Uruguay[ID1351] - Uzbekistan[ID1352] - Vanuatu[ID1353] - Venezuela[ID1354] - Viet Nam[ID1355] - Yemen[ID1356] - Zambia[ID1357] - Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
![Page 58: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/58.jpg)
58
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
![Page 59: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/59.jpg)
59
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
![Page 60: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/60.jpg)
60
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
![Page 61: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/61.jpg)
61
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
![Page 62: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/62.jpg)
62
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
![Page 63: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/63.jpg)
63
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
![Page 64: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/64.jpg)
64
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
![Page 65: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/65.jpg)
65
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
![Page 66: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/66.jpg)
66
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
![Page 67: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/67.jpg)
67
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
![Page 68: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/68.jpg)
68
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
5. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
![Page 69: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/69.jpg)
69
Country of residence (EU member states):[ID1636] - Austria[ID1637] - Belgium[ID1638] - Bulgaria[ID1639] - Croatia[ID1640] - Cyprus[ID1641] - Czechia[ID1642] - Denmark[ID1643] - Estonia[ID1644] - Finland[ID1645] - France[ID1646] - Germany[ID1647] - Greece[ID1648] - Hungary[ID1649] - Ireland[ID1650] - Italy[ID1651] - Latvia[ID1652] - Lithuania[ID1653] - Luxembourg[ID1654] - Malta[ID1655] - Netherlands[ID1656] - Poland[ID1657] - Portugal[ID1658] - Romania[ID1659] - Slovak Republic[ID1660] - Slovenia[ID1661] - Spain[ID1662] - Sweden
Country of residence (Non- EU member sate):[ID1664] - Afghanistan[ID1665] - Albania[ID1666] - Algeria[ID1667] - Andorra[ID1668] - Angola[ID1669] - Antigua and Barbuda[ID1670] - Argentina[ID1671] - Armenia[ID1672] - Australia[ID1673] - Austria[ID1674] - Azerbaijan[ID1675] - Bahamas[ID1676] - Bahrain[ID1677] - Bangladesh[ID1678] - Barbados[ID1679] - Belarus
![Page 70: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/70.jpg)
70
[ID1680] - Belgium[ID1681] - Belize[ID1682] - Benin[ID1683] - Bhutan[ID1684] - Bolivia[ID1685] - Bosnia and Herzegovina[ID1686] - Botswana[ID1687] - Brazil[ID1688] - Brunei Darussalam[ID1689] - Bulgaria[ID1690] - Burkina Faso[ID1691] - Burundi[ID1692] - Cabo Verde[ID1693] - Cambodia[ID1694] - Cameroon[ID1695] - Canada[ID1696] - Central African Republic[ID1697] - Chad[ID1698] - Chile[ID1699] - China[ID1700] - Colombia[ID1701] - Comoros[ID1702] - Congo[ID1703] - Costa Rica[ID1708] - Côte D'Ivoire[ID1704] - Croatia[ID1705] - Cuba[ID1706] - Cyprus[ID1707] - Czechia[ID1709] - Democratic Republic of the Congo[ID1710] - Denmark[ID1711] - Djibouti[ID1712] - Dominica[ID1713] - Dominican Republic[ID1714] - Ecuador[ID1715] - Egypt[ID1716] - El Salvador[ID1717] - Equatorial Guinea[ID1718] - Eritrea[ID1719] - Estonia[ID1720] - Eswatini[ID1721] - Ethiopia[ID1722] - Fiji[ID1723] - Finland[ID1724] - France[ID1725] - Gabon[ID1726] - Gambia
![Page 71: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/71.jpg)
71
[ID1727] - Georgia[ID1728] - Germany[ID1729] - Ghana[ID1730] - Greece[ID1731] - Grenada[ID1732] - Guatemala[ID1733] - Guinea[ID1734] - Guinea Bissau[ID1735] - Guyana[ID1736] - Haiti[ID1737] - Honduras[ID1738] - Hungary[ID1739] - Iceland[ID1740] - India[ID1741] - Indonesia[ID1742] - Iran[ID1743] - Iraq[ID1744] - Ireland[ID1745] - Israel[ID1746] - Italy[ID1747] - Jamaica[ID1748] - Japan[ID1749] - Jordan[ID1750] - Kazakhstan[ID1751] - Kenya[ID1752] - Kiribati[ID1753] - Kuwait[ID1754] - Kyrgyzstan[ID1755] - Laos[ID1756] - Latvia[ID1757] - Lebanon[ID1758] - Lesotho[ID1759] - Liberia[ID1760] - Libya[ID1761] - Liechtenstein[ID1762] - Lithuania[ID1763] - Luxembourg[ID1764] - Madagascar[ID1765] - Malawi[ID1766] - Malaysia[ID1767] - Maldives[ID1768] - Mali[ID1769] - Malta[ID1770] - Marshall Islands[ID1771] - Mauritania[ID1772] - Mauritius[ID1773] - Mexico
![Page 72: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/72.jpg)
72
[ID1774] - Micronesia[ID1775] - Monaco[ID1776] - Mongolia[ID1777] - Montenegro[ID1778] - Morocco[ID1779] - Mozambique[ID1780] - Myanmar[ID1781] - Namibia[ID1782] - Nauru[ID1783] - Nepal[ID1784] - Netherlands[ID1785] - New Zealand[ID1786] - Nicaragua[ID1787] - Niger[ID1788] - Nigeria[ID1789] - North Korea[ID1793] - North Macedonia[ID1794] - Norway[ID1795] - Oman[ID1796] - Pakistan[ID1797] - Palau[ID1798] - Panama[ID1799] - Papua New Guinea[ID1800] - Paraguay[ID1801] - Peru[ID1802] - Philippines[ID1803] - Poland[ID1804] - Portugal[ID1805] - Qatar[ID1806] - Republic of Moldova[ID1807] - Romania[ID1808] - Russian Federation[ID1809] - Rwanda[ID1810] - Saint Kitts and Nevis[ID1811] - Saint Lucia[ID1812] - Saint Vincent and the Grenadines[ID1813] - Samoa[ID1814] - San Marino[ID1815] - Sao Tome and Principe[ID1816] - Saudi Arabia[ID1817] - Senegal[ID1818] - Serbia[ID1819] - Seychelles[ID1820] - Sierra Leone[ID1821] - Singapore[ID1822] - Slovakia[ID1823] - Slovenia
![Page 73: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/73.jpg)
73
[ID1824] - Solomon Islands[ID1825] - Somalia[ID1826] - South Africa[ID1827] - South Korea[ID1828] - South Sudan[ID1829] - Spain[ID1830] - Sri Lanka[ID1831] - Sudan[ID1832] - Suriname[ID1833] - Sweden[ID1834] - Switzerland[ID1835] - Syrian Arab Republic[ID1836] - Tajikistan[ID1837] - Tanzania[ID1838] - Thailand[ID1839] - Timor-Leste[ID1840] - Togo[ID1841] - Tonga[ID1842] - Trinidad and Tobago[ID1843] - Tunisia[ID1844] - Turkey[ID1845] - Turkmenistan[ID1846] - Tuvalu[ID1847] - Uganda[ID1848] - Ukraine[ID1849] - United Arab Emirates[ID1850] - United Kingdom[ID1851] - United States of America[ID1852] - Uruguay[ID1853] - Uzbekistan[ID1854] - Vanuatu[ID1855] - Venezuela[ID1856] - Viet Nam[ID1857] - Yemen[ID1858] - Zambia[ID1859] - Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
![Page 74: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/74.jpg)
74
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
![Page 75: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/75.jpg)
75
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
![Page 76: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/76.jpg)
76
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
![Page 77: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/77.jpg)
77
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
![Page 78: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/78.jpg)
78
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
![Page 79: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/79.jpg)
79
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
![Page 80: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/80.jpg)
80
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
![Page 81: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/81.jpg)
81
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
![Page 82: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/82.jpg)
82
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
![Page 83: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/83.jpg)
83
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
![Page 84: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/84.jpg)
84
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
6. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
![Page 85: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/85.jpg)
85
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
![Page 86: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/86.jpg)
86
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
![Page 87: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/87.jpg)
87
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
![Page 88: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/88.jpg)
88
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
![Page 89: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/89.jpg)
89
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
![Page 90: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/90.jpg)
90
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
![Page 91: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/91.jpg)
91
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
![Page 92: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/92.jpg)
92
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
![Page 93: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/93.jpg)
93
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
![Page 94: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/94.jpg)
94
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
![Page 95: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/95.jpg)
95
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
![Page 96: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/96.jpg)
96
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
![Page 97: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/97.jpg)
97
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
![Page 98: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/98.jpg)
98
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
![Page 99: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/99.jpg)
99
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
![Page 100: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/100.jpg)
100
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
7. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
![Page 101: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/101.jpg)
101
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
![Page 102: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/102.jpg)
102
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
![Page 103: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/103.jpg)
103
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
![Page 104: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/104.jpg)
104
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
![Page 105: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/105.jpg)
105
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
![Page 106: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/106.jpg)
106
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
![Page 107: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/107.jpg)
107
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
![Page 108: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/108.jpg)
108
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
![Page 109: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/109.jpg)
109
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
![Page 110: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/110.jpg)
110
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
![Page 111: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/111.jpg)
111
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
![Page 112: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/112.jpg)
112
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
![Page 113: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/113.jpg)
113
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
![Page 114: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/114.jpg)
114
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
![Page 115: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/115.jpg)
115
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
![Page 116: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/116.jpg)
116
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
8. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
![Page 117: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/117.jpg)
117
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
![Page 118: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/118.jpg)
118
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
![Page 119: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/119.jpg)
119
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
![Page 120: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/120.jpg)
120
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
![Page 121: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/121.jpg)
121
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
![Page 122: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/122.jpg)
122
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
![Page 123: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/123.jpg)
123
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
![Page 124: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/124.jpg)
124
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
![Page 125: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/125.jpg)
125
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
![Page 126: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/126.jpg)
126
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
![Page 127: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/127.jpg)
127
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
![Page 128: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/128.jpg)
128
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
![Page 129: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/129.jpg)
129
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
![Page 130: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/130.jpg)
130
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
![Page 131: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/131.jpg)
131
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
![Page 132: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/132.jpg)
132
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
9. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
![Page 133: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/133.jpg)
133
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
![Page 134: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/134.jpg)
134
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
![Page 135: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/135.jpg)
135
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
![Page 136: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/136.jpg)
136
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
![Page 137: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/137.jpg)
137
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
![Page 138: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/138.jpg)
138
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
![Page 139: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/139.jpg)
139
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
![Page 140: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/140.jpg)
140
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
![Page 141: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/141.jpg)
141
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
![Page 142: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/142.jpg)
142
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
![Page 143: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/143.jpg)
143
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
![Page 144: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/144.jpg)
144
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
![Page 145: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/145.jpg)
145
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
![Page 146: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/146.jpg)
146
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
![Page 147: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/147.jpg)
147
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
![Page 148: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/148.jpg)
148
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
10. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
![Page 149: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/149.jpg)
149
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
![Page 150: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/150.jpg)
150
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
![Page 151: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/151.jpg)
151
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
![Page 152: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/152.jpg)
152
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
![Page 153: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/153.jpg)
153
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
![Page 154: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/154.jpg)
154
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
![Page 155: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/155.jpg)
155
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
![Page 156: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/156.jpg)
156
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
![Page 157: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/157.jpg)
157
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
![Page 158: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/158.jpg)
158
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
![Page 159: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/159.jpg)
159
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
![Page 160: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/160.jpg)
160
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
![Page 161: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/161.jpg)
161
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
![Page 162: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/162.jpg)
162
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
![Page 163: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/163.jpg)
163
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
![Page 164: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/164.jpg)
164
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
11. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
![Page 165: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/165.jpg)
165
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
![Page 166: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/166.jpg)
166
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
![Page 167: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/167.jpg)
167
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
![Page 168: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/168.jpg)
168
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
![Page 169: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/169.jpg)
169
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
![Page 170: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/170.jpg)
170
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
![Page 171: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/171.jpg)
171
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
![Page 172: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/172.jpg)
172
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
![Page 173: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/173.jpg)
173
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
![Page 174: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/174.jpg)
174
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
![Page 175: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/175.jpg)
175
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
![Page 176: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/176.jpg)
176
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
![Page 177: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/177.jpg)
177
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
![Page 178: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/178.jpg)
178
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
![Page 179: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/179.jpg)
179
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
![Page 180: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/180.jpg)
180
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
12. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
![Page 181: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/181.jpg)
181
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
![Page 182: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/182.jpg)
182
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
![Page 183: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/183.jpg)
183
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
![Page 184: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/184.jpg)
184
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
![Page 185: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/185.jpg)
185
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
![Page 186: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/186.jpg)
186
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
![Page 187: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/187.jpg)
187
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
![Page 188: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/188.jpg)
188
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
![Page 189: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/189.jpg)
189
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
![Page 190: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/190.jpg)
190
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
![Page 191: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/191.jpg)
191
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
![Page 192: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/192.jpg)
192
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
![Page 193: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/193.jpg)
193
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
![Page 194: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/194.jpg)
194
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
![Page 195: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/195.jpg)
195
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
![Page 196: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/196.jpg)
196
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
13. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
![Page 197: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/197.jpg)
197
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
![Page 198: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/198.jpg)
198
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
![Page 199: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/199.jpg)
199
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
![Page 200: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/200.jpg)
200
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
![Page 201: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/201.jpg)
201
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
![Page 202: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/202.jpg)
202
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
![Page 203: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/203.jpg)
203
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
![Page 204: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/204.jpg)
204
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
![Page 205: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/205.jpg)
205
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
![Page 206: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/206.jpg)
206
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
![Page 207: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/207.jpg)
207
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
![Page 208: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/208.jpg)
208
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
![Page 209: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/209.jpg)
209
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
![Page 210: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/210.jpg)
210
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
![Page 211: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/211.jpg)
211
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
![Page 212: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/212.jpg)
212
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
14. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
![Page 213: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/213.jpg)
213
Country of residence (EU member states):- Austria- Belgium- Bulgaria- Croatia- Cyprus- Czechia- Denmark- Estonia- Finland- France- Germany- Greece- Hungary- Ireland- Italy- Latvia- Lithuania- Luxembourg- Malta- Netherlands- Poland- Portugal- Romania- Slovak Republic- Slovenia- Spain- Sweden
Country of residence (Non- EU member sate):- Afghanistan- Albania- Algeria- Andorra- Angola- Antigua and Barbuda- Argentina- Armenia- Australia- Austria- Azerbaijan- Bahamas- Bahrain- Bangladesh- Barbados- Belarus
![Page 214: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/214.jpg)
214
- Belgium- Belize- Benin- Bhutan- Bolivia- Bosnia and Herzegovina- Botswana- Brazil- Brunei Darussalam- Bulgaria- Burkina Faso- Burundi- Cabo Verde- Cambodia- Cameroon- Canada- Central African Republic- Chad- Chile- China- Colombia- Comoros- Congo- Costa Rica- Côte D'Ivoire- Croatia- Cuba- Cyprus- Czechia- Democratic Republic of the Congo- Denmark- Djibouti- Dominica- Dominican Republic- Ecuador- Egypt- El Salvador- Equatorial Guinea- Eritrea- Estonia- Eswatini- Ethiopia- Fiji- Finland- France- Gabon- Gambia
![Page 215: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/215.jpg)
215
- Georgia- Germany- Ghana- Greece- Grenada- Guatemala- Guinea- Guinea Bissau- Guyana- Haiti- Honduras- Hungary- Iceland- India- Indonesia- Iran- Iraq- Ireland- Israel- Italy- Jamaica- Japan- Jordan- Kazakhstan- Kenya- Kiribati- Kuwait- Kyrgyzstan- Laos- Latvia- Lebanon- Lesotho- Liberia- Libya- Liechtenstein- Lithuania- Luxembourg- Madagascar- Malawi- Malaysia- Maldives- Mali- Malta- Marshall Islands- Mauritania- Mauritius- Mexico
![Page 216: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/216.jpg)
216
- Micronesia- Monaco- Mongolia- Montenegro- Morocco- Mozambique- Myanmar- Namibia- Nauru- Nepal- Netherlands- New Zealand- Nicaragua- Niger- Nigeria- North Korea- North Macedonia- Norway- Oman- Pakistan- Palau- Panama- Papua New Guinea- Paraguay- Peru- Philippines- Poland- Portugal- Qatar- Republic of Moldova- Romania- Russian Federation- Rwanda- Saint Kitts and Nevis- Saint Lucia- Saint Vincent and the Grenadines- Samoa- San Marino- Sao Tome and Principe- Saudi Arabia- Senegal- Serbia- Seychelles- Sierra Leone- Singapore- Slovakia- Slovenia
![Page 217: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/217.jpg)
217
- Solomon Islands- Somalia- South Africa- South Korea- South Sudan- Spain- Sri Lanka- Sudan- Suriname- Sweden- Switzerland- Syrian Arab Republic- Tajikistan- Tanzania- Thailand- Timor-Leste- Togo- Tonga- Trinidad and Tobago- Tunisia- Turkey- Turkmenistan- Tuvalu- Uganda- Ukraine- United Arab Emirates- United Kingdom- United States of America- Uruguay- Uzbekistan- Vanuatu- Venezuela- Viet Nam- Yemen- Zambia- Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
![Page 218: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/218.jpg)
218
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
![Page 219: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/219.jpg)
219
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
![Page 220: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/220.jpg)
220
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
![Page 221: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/221.jpg)
221
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
![Page 222: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/222.jpg)
222
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
![Page 223: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/223.jpg)
223
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
![Page 224: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/224.jpg)
224
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
![Page 225: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/225.jpg)
225
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
![Page 226: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/226.jpg)
226
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
![Page 227: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/227.jpg)
227
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
![Page 228: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/228.jpg)
228
months
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
Please, if you have more patients to add, go to the next section. If you have finished, go to the Submit section to finish the survey.
15. PATIENT-SPECIFIC QUESTIONS
* Age of the patient at the time of SARS-CoV-2 infection:
* Sex:FemaleMale
![Page 229: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/229.jpg)
229
Country of residence (EU member states):[ID81] - Austria[ID388] - Belgium[ID389] - Bulgaria[ID390] - Croatia[ID391] - Cyprus[ID392] - Czechia[ID393] - Denmark[ID394] - Estonia[ID395] - Finland[ID396] - France[ID397] - Germany[ID398] - Greece[ID399] - Hungary[ID400] - Ireland[ID401] - Italy[ID402] - Latvia[ID403] - Lithuania[ID404] - Luxembourg[ID405] - Malta[ID406] - Netherlands[ID407] - Poland[ID408] - Portugal[ID409] - Romania[ID410] - Slovak Republic[ID411] - Slovenia[ID412] - Spain[ID413] - Sweden
Country of residence (Non- EU member sate):[ID415] - Afghanistan[ID416] - Albania[ID417] - Algeria[ID418] - Andorra[ID419] - Angola[ID420] - Antigua and Barbuda[ID421] - Argentina[ID422] - Armenia[ID423] - Australia[ID424] - Austria[ID425] - Azerbaijan[ID426] - Bahamas[ID427] - Bahrain[ID428] - Bangladesh[ID429] - Barbados[ID430] - Belarus
![Page 230: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/230.jpg)
230
[ID431] - Belgium[ID432] - Belize[ID433] - Benin[ID434] - Bhutan[ID435] - Bolivia[ID436] - Bosnia and Herzegovina[ID437] - Botswana[ID438] - Brazil[ID439] - Brunei Darussalam[ID440] - Bulgaria[ID441] - Burkina Faso[ID442] - Burundi[ID443] - Cabo Verde[ID444] - Cambodia[ID445] - Cameroon[ID446] - Canada[ID447] - Central African Republic[ID448] - Chad[ID449] - Chile[ID450] - China[ID451] - Colombia[ID452] - Comoros[ID453] - Congo[ID454] - Costa Rica[ID459] - Côte D'Ivoire[ID455] - Croatia[ID456] - Cuba[ID457] - Cyprus[ID458] - Czechia[ID460] - Democratic Republic of the Congo[ID461] - Denmark[ID462] - Djibouti[ID463] - Dominica[ID464] - Dominican Republic[ID465] - Ecuador[ID466] - Egypt[ID467] - El Salvador[ID468] - Equatorial Guinea[ID469] - Eritrea[ID470] - Estonia[ID471] - Eswatini[ID472] - Ethiopia[ID473] - Fiji[ID474] - Finland[ID475] - France[ID476] - Gabon[ID477] - Gambia
![Page 231: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/231.jpg)
231
[ID478] - Georgia[ID479] - Germany[ID480] - Ghana[ID481] - Greece[ID482] - Grenada[ID483] - Guatemala[ID484] - Guinea[ID485] - Guinea Bissau[ID486] - Guyana[ID487] - Haiti[ID488] - Honduras[ID489] - Hungary[ID490] - Iceland[ID491] - India[ID492] - Indonesia[ID493] - Iran[ID494] - Iraq[ID495] - Ireland[ID496] - Israel[ID497] - Italy[ID498] - Jamaica[ID499] - Japan[ID500] - Jordan[ID501] - Kazakhstan[ID502] - Kenya[ID503] - Kiribati[ID504] - Kuwait[ID505] - Kyrgyzstan[ID506] - Laos[ID507] - Latvia[ID508] - Lebanon[ID509] - Lesotho[ID510] - Liberia[ID511] - Libya[ID512] - Liechtenstein[ID513] - Lithuania[ID514] - Luxembourg[ID515] - Madagascar[ID516] - Malawi[ID517] - Malaysia[ID518] - Maldives[ID519] - Mali[ID520] - Malta[ID521] - Marshall Islands[ID522] - Mauritania[ID523] - Mauritius[ID524] - Mexico
![Page 232: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/232.jpg)
232
[ID525] - Micronesia[ID526] - Monaco[ID527] - Mongolia[ID528] - Montenegro[ID529] - Morocco[ID530] - Mozambique[ID531] - Myanmar[ID532] - Namibia[ID533] - Nauru[ID534] - Nepal[ID535] - Netherlands[ID536] - New Zealand[ID537] - Nicaragua[ID538] - Niger[ID539] - Nigeria[ID540] - North Korea[ID541] - North Macedonia[ID542] - Norway[ID543] - Oman[ID544] - Pakistan[ID545] - Palau[ID546] - Panama[ID547] - Papua New Guinea[ID548] - Paraguay[ID549] - Peru[ID550] - Philippines[ID551] - Poland[ID552] - Portugal[ID553] - Qatar[ID554] - Republic of Moldova[ID555] - Romania[ID556] - Russian Federation[ID557] - Rwanda[ID558] - Saint Kitts and Nevis[ID559] - Saint Lucia[ID560] - Saint Vincent and the Grenadines[ID561] - Samoa[ID562] - San Marino[ID563] - Sao Tome and Principe[ID564] - Saudi Arabia[ID565] - Senegal[ID566] - Serbia[ID567] - Seychelles[ID568] - Sierra Leone[ID569] - Singapore[ID570] - Slovakia[ID571] - Slovenia
![Page 233: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/233.jpg)
233
[ID572] - Solomon Islands[ID573] - Somalia[ID574] - South Africa[ID575] - South Korea[ID576] - South Sudan[ID577] - Spain[ID578] - Sri Lanka[ID579] - Sudan[ID580] - Suriname[ID581] - Sweden[ID582] - Switzerland[ID583] - Syrian Arab Republic[ID584] - Tajikistan[ID585] - Tanzania[ID586] - Thailand[ID587] - Timor-Leste[ID588] - Togo[ID589] - Tonga[ID590] - Trinidad and Tobago[ID591] - Tunisia[ID592] - Turkey[ID593] - Turkmenistan[ID594] - Tuvalu[ID595] - Uganda[ID596] - Ukraine[ID597] - United Arab Emirates[ID598] - United Kingdom[ID599] - United States of America[ID600] - Uruguay[ID601] - Uzbekistan[ID602] - Vanuatu[ID603] - Venezuela[ID604] - Viet Nam[ID605] - Yemen[ID606] - Zambia[ID607] - Zimbabwe
* City of residence:
* Type of transplantation:Hematopoietic stem cellHeartIntestine/MultivisceralKidney
![Page 234: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/234.jpg)
234
months
LiverLungPancreasCombined
* Please, select type of transplantations received:between 2 and 7 choices
HeartHematopoietic stem cellIntestine/MultivisceralKidneyLiverLungPancreas
* Primary diagnosis (i.e., disease that led to transplantation):
* Age of the patient at transplantation procedure (if more than one transplant, please write the last one):
Details of patient with confirmed SARS-CoV-2 infection according to the WHO definition
a. Health status of the patient at the time of SARS-CoV-2 infection
* Post-transplant health status at the time of SARS-CoV-2 infection:1-Poor2-Fair3-Average4-Good
* Co-morbidities at the time of SARS-CoV-2 infection:NoneHypertensionCardiac disordersPulmonary disordersDiabetesObesityOther
Please, specify cardiac disorder:
![Page 235: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/235.jpg)
235
Please, specify pulmonary disorder:
Please, specify other co-morbidities at the time of SARS-CoV-2 infection:
b. Immunological status of the patient at the latest follow up visit (<6 months) before SARS-CoV-2 infection
* Ongoing immunosuppression:TacrolimusCyclosporineMycophenolate mofetil/mycophenolic acidEverolimus/SirolimusPrednisoneRituximabOtherNone
* Please, specify other immunosuppressive agent:
* Has the patient received any monoclonal antibody and when?Rituximab (anti-CD20)Alemtuzumab (anti-CD52)Basilixumab/daclizumab (anti-CD25)OtherNone
* Please, specify dates (dd/mm/yy) for each dose of Rituximab:
* Please, specify dates (dd/mm/yy) for each dose of Alemtuzumab:
* Please, specify dates (dd/mm/yy) for each dose of Basilixumab/daclizumab:
![Page 236: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/236.jpg)
236
* Please, specify the monoclonal ab and dates (dd/mm/yy) for each dose:
* Ongoing immunological complications at the time of SARS-CoV-2 infection:NoneAcute rejectionChronic rejectionGraft-versus-host disease (GVHD)Other
* Please, specify other immunological complications:
* Ongoing infectious complications at the time of SARS-CoV-2 infection:NoneBacterial infectionViral infectionFungal infectionOther
* Please, select agent of bacterial infection:Acinetobacter baumaniiAntimicrobial-resistant enterococciBurkholderia cepacia groupCampylobacter sppClostridium difficileEnterobacter sppEnterococcus sppEscherichia coliKlebsiella sppLegionella sppListeria monocytogenesMethicillin-resistant staphylococciMultidrug-resistant gram-negative bacilliMycobacterium tuberculosisMycoplasma sppNocardia sppNontuberculous mycobacteriaOther gram-negative bacteriaOther gram-positive bacteriaPseudomonas aeruginosaS. epidermidisSalmonella sppSerratia spp
![Page 237: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/237.jpg)
237
Staphylococcus aureusStenotrophomonas maltophiliaStreptococcus pneumoniaeOther
* Please, select agent of viral infection:AdenovirusBK polyomavirusCMVEBVHBVHCVHHV6HHV8HSVInfluenzaJC polyomavirusMetapneumovirusNorovirusParainfluenza virusParvovirus B19RhinovirusRotavirusRSVVZVOther
* Please, select agent of fungal infection:Aspergillus sppCandida sppCryptococcus neoformansEndemic mycosisMucormycosisPneumocystis jiroveciiOther
* If any other, please specify:
* Leukocytes:NormalLeukocytosisLeukopeniaUnknown or not evaluated
![Page 238: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/238.jpg)
238
* Neutrophils:NormalNeutrophiliaNeutropenia < 1000/mmcNeutropenia < 500/mmcUnknown or not evaluated
* Lymphocytes:NormalLymphocytosisLymphopenia < 1000/mmcLymphopenia < 500/mmcUnknown or not evaluated
* Immunoglobulins:NormalReduced <3 percentile for ageUnknown or not evaluated
c. SARS-CoV-2 infection
* Date of diagnosis:
* Diagnostic test:Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Antigen-Rapid Diagnostic Test (RDT) confirmed by a positive Nucleic Acid Amplification Test (NAAT)Other
* Please, specify other diagnostic test:
* Source of infection:Households with a probable or confirmed COVID-19Close contact with a probable or confirmed COVID-19 case at schoolClose contact with a probable or confirmed COVID-19 case at the hospital (during admissions or follow-up visits)Close contact with a probable or confirmed COVID-19 case out of school and out of the hospital (other than households contacts)UnknownOther
* Please, specify other source of infection:
![Page 239: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/239.jpg)
239
weeks
* Test employed to monitor the recovery from SARS-CoV-2 infection (i.e. test employed to assess SARS-CoV-2 negativization after diagnosis):
Nucleic Acid Amplification Test (NAAT)Antigen-Rapid Diagnostic Test (RDT)Viral cultureNo test, the patient was considered recovered after 21 days from the resolution of symptomsOther
* Please, specify other type of monitoring:
* Duration of the infection (i.e. duration of SARS-CoV-2 positivity from diagnosis) as determined by the diagnostic test(s) selected
< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of the infection:
d. Clinical manifestations of SARS-CoV-2 infection
* Symptoms:None/asymptomatic infectionFeverHeadacheFatigueSore throatRespiratory symptomsGastrointestinal symptomsMuscle or body achesLoss of taste or smellMultisystem inflammatory syndrome in children (MIS-C)Other
* Please, specify type of respiratory symptoms:
![Page 240: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/240.jpg)
240
* Please, specify type of gastrointestinal symptoms:
* Please, specify other type of symptoms:
* Lung imaging:NoneChest X-raysChest CT scanOther
* Please, specify the X-rays result:
* Please, specify the CT scan result:
* Please, specify other lung imaging and results:
* Injury to the transplanted graft (clinical, biochemical or radiological evidence):YesNoNot tested
* Please, specify the type of injury to the transplanted graft:
* Duration of symptoms:Asymptomatic infection< 1 week< 2 weeks< 3 weeks< 4 weeksUnknownOther
* Please, specify other duration of symptoms:
![Page 241: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/241.jpg)
241
days
weeks
* Outcome:Complete recoveryRecovery with sequelaeDeath
* Please, specify the sequelae:
Please, specify the Date of death:
e. SARS-CoV-2 management
* Respiratory support for SARS-CoV-2 infection:NoneOxygenNon-invasive ventilationInvasive mechanical ventilationHigh-frequency oscillatory ventilation (HFOV)ECMO
* Please, specify total duration:
* Pharmacological treatment of SARS-CoV-2 infection:NoneReduction of immunosuppressionStop immunosuppressionSteroid treatmentRemdesivirAntiviral treatment (not including remdesivir)Antibiotic treatmentHeparinHydroxychloroquineConvalescent plasma therapyOther
* Please, specify which IS and duration:
*
![Page 242: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/242.jpg)
242
days* Please, specify the duration of the stop immunosupression:
* Please, specify dose (mg/kg/day) and duration (days) of remdesivir treatment:
![Page 243: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/243.jpg)
243
Please, specify steroid, other antiviral, antibiotic and/or heparin treatment:Name of drug Duration (days) Administration route
1
2
3
4
![Page 244: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/244.jpg)
244
* Please, specify dose (mg/kg/day) and duration (days) of hydroxychloroquine treatment:
* Please, specify dose and number of administrations:
* Please, specify other type of drugs:
* Management of SARS-CoV-2 infection:None (the patient did not receive any medical support or follow up)Home medical visitsTelematic follow-upHospital admissionPediatric Intensive Care Unit (PICU) admissionOther
* Please, specify the indication of hospital admission:
* Please, specify the indication of PICU admission:
* Please, specify other:
SUBMIT
If you have more than fifteen cases to report, please submit a new survey.
![Page 245: EPIDEMIOLOGICAL AND MEDICAL BURDEN OF THE COVID-19](https://reader031.vdocuments.us/reader031/viewer/2022011807/61d3ecc4ed4362208f4c4e1e/html5/thumbnails/245.jpg)
245